دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward
Brandon P Moss, Deborah M Miller
doi : 10.1177/13524585211069668
First Published January 11, 2022; pp. 171–172
Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy
Luciana Midaglia, Susana Otero, Francesc Baró, Xavier Montalban, Mar Tintoré
doi : 10.1177/1352458520952022
First Published August 28, 2020; pp. 173–182
Sex hormones play a role in both the risk and the prognosis of multiple sclerosis (MS). Considering all stages of women’s reproductive life, data regarding the influence of menopause on MS and vice versa are scarce.
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes
Patricia K Coyle, Olga Syritsyna
doi : 10.1177/13524585211010450
First Published January 8, 2022; pp. 183–185
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No
Robert A Bermel
doi : 10.1177/13524585211062169
First Published December 16, 2021; pp. 185–187
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Commentary
Robert J Fox, Mar Tintore
doi : 10.1177/13524585211049073
First Published December 16, 2021; pp. 187–188
Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome
Guillaume Bellanger, Damien Biotti, Gilles Adam, Jean Darcourt, Margaux Roques, Sofia Patsoura, Julien Savatovsky, Michael Obadia, Nicolas Menjot de Champfleur, Mahmoud Charif, Pierre Labauge, Francois Cotton, Françoise Durand Dubief, Thomas Tourdias, Cecile Dulau, Stéphane Kremer, Jérôme De Sèze, Jonathan Ciron, Fanny Varenne, Alain Viguier, Fleur Lerebours, Vincent Larrue, Christophe Cognard, Fabrice Bonneville
doi : 10.1177/13524585211012349
First Published May 14, 2021; pp. 189–197
Leptomeningeal enhancement (LME) is a key feature of Susac syndrome (SuS) but is only occasionally depicted on post-contrast T1-weighted images (T1-WI).
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI
Yufan Zheng, Jessica Dudman, Jacqueline T Chen, Kedar R Mahajan, Danielle Herman, Robert J Fox, Daniel Ontaneda, Bruce D Trapp, Kunio Nakamura
doi : 10.1177/13524585211014760
First Published May 20, 2021; pp. 198–205
Detecting cortical demyelination using magnetic resonance imaging (MRI) in multiple sclerosis (MS) remains a challenge. Magnetization transfer ratio (MTR), T1-weighted/T2-weighted ratio (T1T2R), and T2-weighted (T2w) signal are sensitive to cortical demyelination, but their accuracy is unknown.
Altered anterior default mode network dynamics in progressive multiple sclerosis
Giulia Bommarito, Anjali Tarun, Younes Farouj, Maria Giulia Preti, Maria Petracca, Amgad Droby, Mohamed Mounir El Mendili, Matilde Inglese, Dimitri Van De Ville
doi : 10.1177/13524585211018116
First Published June 14, 2021; pp. 206–216
Modifications in brain function remain relatively unexplored in progressive multiple sclerosis (PMS), despite their potential to provide new insights into the pathophysiology of the disease at this stage.
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis
Silvia Messina, Romina Mariano, Adriana Roca-Fernandez, Ana Cavey, Maciej Jurynczyk, Maria Isabel Leite, Massimiliano Calabrese, Mark Jenkinson, Jacqueline Palace
doi : 10.1177/13524585211018987
First Published May 28, 2021; pp. 217–227
Identifying magnetic resonance imaging (MRI) markers in myelin-oligodendrocytes-glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder-aquaporin-4 positive (NMOSD-AQP4) and multiple sclerosis (MS) is essential for establishing objective outcome measures.
Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation
Anne Kever, Korhan Buyukturkoglu, Seth N Levin, Claire S Riley, Philip De Jager, Victoria M Leavitt
doi : 10.1177/13524585211018349
First Published May 26, 2021; pp. 228–236
Humans are inherently social, biologically programmed to connect with others. Social connections are known to impact mental and physical health.
A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser, Tim Spelman
doi : 10.1177/13524585211019649
First Published June 3, 2021; pp. 237–246
Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations.
Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey
Anne Kever, Victoria M Leavitt
doi : 10.1177/13524585211037581
First Published September 9, 2021; pp. 247–256
Individuals with multiple sclerosis (MS) regularly report making strategic decisions about whether to share their diagnosis or keep it a secret; for many, this represents a key stressor. Surprisingly, the impact of disclosure and concealment are understudied in MS and a formal measurement instrument is lacking. We developed the Diagnosis Disclosure and Concealment in MS (DISCO-MS) survey, a self-assessment tool evaluating (1) frequency of concealment behaviors and (2) expected consequences of diagnosis disclosure in persons with MS.
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
Steffen Pfeuffer, Leoni Rolfes, Jana Hackert, Konstanze Kleinschnitz, Tobias Ruck, Heinz Wiendl, Luisa Klotz, Christoph Kleinschnitz, Sven G Meuth, Refik Pul
doi : 10.1177/13524585211012227
First Published May 12, 2021; pp. 257–268
Oral cladribine has been approved for the treatment of relapsing multiple sclerosis (MS) yet real-world evidence regarding its effectiveness and safety remains scarce.
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis
Feray Güngör, Ela Tarakci, Zeynep Özdemir-Acar, Aysun Soysal
doi : 10.1177/13524585211012202
First Published April 28, 2021; pp. 269–279
Pilates-based core stability training (PBCST) is a controlled form of exercise that may improve the transmission of torque from the upper extremities and trunk to the lower extremities by enabling the core muscles to activate effectively.
Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis
Mini Singh, Ronald Gavidia, Galit Levi Dunietz, Elizabeth Washnock-Schmid, Andrew R Romeo, Shelley Hershner, Ronald D Chervin, Tiffany J Braley
doi : 10.1177/13524585211013014
First Published May 28, 2021; pp. 280–288
Improved screening for obstructive sleep apnea (OSA) could enhance multiple sclerosis (MS) clinical care; yet the utility of current screening tools for OSA have yet to be evaluated in persons with multiple sclerosis (PwMS).
The timed 25-foot walk in a large cohort of multiple sclerosis patients
Anissa Kalinowski, Gary Cutter, Nina Bozinov, Jessica A Hinman, Michael Hittle, Robert Motl, Michelle Odden, Lorene M Nelson
doi : 10.1177/13524585211017013
First Published June 8, 2021; pp. 289–299
The timed 25-foot walk (T25FW) is a key clinical outcome measure in multiple sclerosis patient management and clinical research.
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis
KH Lam, P van Oirschot, B den Teuling, HE Hulst, BA de Jong, BMJ Uitdehaag, V de Groot, J Killestein
doi : 10.1177/13524585211018103
First Published May 26, 2021; pp. 300–308
Early detection and monitoring of cognitive dysfunction in multiple sclerosis (MS) may be enabled with smartphone-adapted tests that allow frequent measurements in the everyday environment.
Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada
Jonathan Roux, Elaine Kingwell, Feng Zhu, Helen Tremlett, Emmanuelle Leray, the BeAMS Study group
doi : 10.1177/13524585211016726
First Published May 28, 2021; pp. 309–322
Persons with multiple sclerosis (PwMS) typically require complex multidisciplinary care, which is rarely formally assessed.
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
Alyssa A Toorop, Theo Rispens, Eva MM Strijbis, Bob W van Oosten, Brigit A de Jong, Bernard MJ Uitdehaag, Joep Killestein, Zoé LE van Kempen
doi : 10.1177/13524585211052168
First Published December 21, 2021; pp. 323–326
In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
Ruth Dobson, Karen Chung
doi : 10.1177/13524585211069922
First Published January 27, 2022; pp. 326–327
